Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression

American Journal of Geriatric Psychiatry

Volumn 17, Issue 9, 2009, Pages 744-751

  Wang, Lucy Y ^a   Shofer, Jane B ^a   Rohde, Kirsten ^a   Hart, Kim L ^a   Hoff, David J ^a   McFall, Yun H ^a   Raskind, Murray A ^a   Peskind, Elaine R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Agitation; Dementia; Norepinephrine; Prazosin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; PRAZOSIN;

AGED; AGGRESSION; AGITATION; ALGORITHM; ALZHEIMER DISEASE; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CAREGIVER BURDEN; CENTRAL NERVOUS SYSTEM; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HALLUCINATION; HEADACHE; HUMAN; HYPOTENSION; INSTITUTIONALIZATION; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NORADRENALIN RELEASE; NURSING HOME; PATHOPHYSIOLOGY; PILOT STUDY; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; RASH; SEDATION; SIDE EFFECT;

EID: 69449092485     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e3181ab8c61     Document Type: Article

References (40)

1. Cohen-Mansfield J, Marx MS, Rosenthal AS: A description of agitation in a nursing home. J Gerontol 1989; 44:M77-M84
2. Selbaek G, Kirkevold O, Engedal K: The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes - a 12-month follow-up study. Am J Geriatr Psychiatry 2008; 16:528-536
3. Swearer JM, Drachman DA, O'Donnell BF, et al: Troublesome and disruptive behaviors in dementia. Relationships to diagnosis and disease severity. J Am Geriatr Soc 1988; 36:784-790
4. Borson S, Liptzin B, Nininger J, et al: Psychiatry and the nursing home. Am J Psychiatry 1987; 144:1412-1418
5. Rabins PV, Mace NL, Lucas MJ: The impact of dementia on the family. JAMA 1982; 248:333-335
6. Steele C, Rovner B, Chase GA, et al: Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990; 147:1049-1051 (Pubitemid 20257519)
7. Alexopoulos GS, Streim J, Carpenter D, et al: Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65(suppl 2):5-99
8. Lyketsos CG, Colenda CC, Beck C, et al: Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006; 14:561-572 (Pubitemid 44036480)
9. Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293:596-608 (Pubitemid 40171242)
10. Katz IR, Jeste DV, Mintzer JE, et al: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60:107-115
11. Kryzhanovskaya LA, Jeste DV, Young CA, et al: A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia. J Clin Psychiatry 2006; 67:933-945 (Pubitemid 44049092)
12. Schneider LS, Tariot PN, Dagerman KS, et al: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355:1525-1538 (Pubitemid 44547805)
13. Street JS, Clark WS, Gannon KS, et al: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57:968-976
14. Streim JE, Porsteinsson AP, Breder CD, et al: A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry 2008; 16:537-550
15. Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14:191-210
16. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934-1943
17. FDA alert. Information for Health Care Professionals, Antipsychotics [FDA Web site], 2008. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/ antipsychotics-conventional.htm. Accessed August 28, 2008
18. Salzman C, Jeste DV, Meyer RE, et al: Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry 2008; 69:889-898 (Pubitemid 351944940)
19. Elrod R, Peskind ER, DiGiacomo L, et al: Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. Am J Psychiatry 1997; 154:25-30 (Pubitemid 27020188)
20. Peskind ER, Wingerson D, Murray S, et al: Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch Gen Psychiatry 1995; 52:774-782
21. Szot P, White SS, Greenup JL, et al: Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J Neurosci 2006; 26:467-478 (Pubitemid 43237111)
22. Szot P, White SS, Greenup JL, et al: Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience 2007; 146:471-480 (Pubitemid 46654630)
23. Hardman JG, Limbird LE, Milinoff PB, et al: Goodman & Gilman's the Pharmacological Basis of Therapeutics, 9th edition. New York, McGraw-Hill, 1996
24. Menkes DB, Baraban JM, Aghajanian GK: Prazosin selectively antagonizes neuronal responses mediated by alpha1-adrenoceptors in brain. Naunyn Schmiedebergs Arch Pharmacol 1981; 317:273-275
25. Peskind ER, Bonner LT, Li G, et al: Adrenergic antagonists for disruptive agitation in nursing home residents with Alzheimer's disease. Neurobiol Aging: The 8th International Conference on Alzheimer's Disease and Related Disorders 2002; 23:S150
26. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944 (Pubitemid 14076461)
27. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
28. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314 (Pubitemid 24382728)
29. Schneider LS, Olin JT, Doody RS, et al: Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S22-S32 (Pubitemid 27303107)
30. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969; 9:179-186
31. R Development Core Team, eds: A Language and Environment for Statistical Computing. Vienna, R Foundation for Statistical Computing, 2007
32. Sultzer DL, Davis SM, Tariot PN, et al: Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008; 165:844-854
33. Tariot PN, Schneider L, Katz IR, et al: Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 2006; 14:767-776 (Pubitemid 44380069)
34. Hoogendijk WJ, Feenstra MG, Botterblom MH, et al: Increased activity of surviving locus ceruleus neurons in Alzheimer's disease. Ann Neurol 1999; 45:82-91 (Pubitemid 29036436)
35. Sharp SI, Ballard CG, Chen CP, et al: Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease. Am J Geriatr Psychiatry 2007; 15:435-437
36. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68:29-39
37. American Psychiatric Association: Practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Am J Psychiatry 2007; 164:1-56
38. Ballard C: Agitation and psychosis in dementia. Am J Geriatr Psychiatry 2007; 15:913-917
39. Peskind ER, Tsuang DW, Bonner LT, et al: Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord 2005; 19:23-28 (Pubitemid 40488660)
40. Ballard C, Margallo-Lana M, Juszczak E, et al: Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005; 330:874 (Pubitemid 40545686)